Results 321 to 330 of about 436,330 (367)

Predicting Favorable Conditions for the Determination of Initial Use of Janus Kinase Inhibitors in Patients with Moderate to Severe Atopic Dermatitis. [PDF]

J Clin Med
Park JH, Oh S, Park J, Choi Y, Lee JH.
europepmc   +1 more source

Do Obesity and Adipose Tissue Cytokines Influence the Response to Janus Kinase Inhibitors in Rheumatoid Arthritis? [PDF]

Nutrients
Novella-Navarro M, Van Den Rym A, López-Pedrera C, Martínez-Feito A, Nieto-Carvalhal B, Reche K, López-Medina C, Escudero-Contreras A, Nozal P, Miranda-Carús ME, Monjo I, De Miguel E, Balsa A, Pérez-De Diego R, Plasencia-Rodríguez C.   +14 more
europepmc   +1 more source

The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias.

Int J Trichology
Balfour AN, Osborne S, Mesinkovska NA.
europepmc   +1 more source

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta-Analysis. [PDF]

Clin Pharmacol Ther
Huang F, Hu D, Fan H, Hu B, Liu Y, Dong W, Liu X, Li Y, Yan D, Ding R, Niu S, Chen L, Nie X, Fang Y.   +13 more
europepmc   +1 more source

Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis. [PDF]

Rheumatology (Oxford)
Ahmed S, Pfeiffer RM, Jackson SS, Song M, Mariette X, Seror R, Engels EA.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Janus kinase inhibitors: efficacy and safety

Current Opinion in Rheumatology, 2023
Purpose of review Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy.
S. Cohen, V. Reddy
semanticscholar   +3 more sources

Efficacy of Janus kinase inhibitors in rheumatoid arthritis

Inflammation Research, 2023
Janus kinase inhibitors (JAKis) is a new therapeutic class in autoimmune and inflammatory diseases. Four molecules are approved in rheumatoid arthritis (RA) in Europe. Recently, questions have raised about adverse events. In this context, a synthesis of the efficacy data of JAKis in RA is of use.We performed a literature review based on published ...
C. Langbour, Jessica René, P. Goupille, Guillermo Carvajal Alegria   +3 more
semanticscholar   +3 more sources

The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta‐analysis of randomized controlled trials

Journal of the European Academy of Dermatology and Venereology, 2023
Janus kinase (JAK) inhibitors have been recently approved by the FDA and are widely used in the treatment of patients with atopic dermatitis. However, a comprehensive safety profile of JAK inhibitors in patients with atopic dermatitis has not been ...
S. Yoon, Kihun Kim, K. Shin, Hoonsoo Kim, Byungsoo Kim, M. Kim, H. Ko, Y. Kim   +7 more
semanticscholar   +1 more source

Janus Kinase Inhibitors and Adverse Events of Acne: A Systematic Review and Meta-Analysis.

JAMA dermatology, 2023
Importance Janus kinase (JAK) inhibitors are increasingly used across a range of dermatologic conditions. Adverse events of acne have been noted in some studies in clinical practice, but the scope of this outcome across JAK inhibitors has not been ...
Jeremy Martinez, Cyriac Manjaly, P. Manjaly, Sophia Ly, Guohai Zhou, John S. Barbieri, A. Mostaghimi   +6 more
semanticscholar   +1 more source